Prevalence of Borrelia burgdorferi sensu lato infection in the Czech Republic.
Roman Chlibek, Jan Smetana, Kate��ina Kybicov��, Martina Malikova, Frederick J Angulo, Alexandra Loew-Baselli, Ye Tan, Ale�� Ond��ej����ek, Gordon Brestrich, Andreas Pilz, Jennifer C Mo��si, James H Stark
Author Information
Roman Chlibek: Military Medical Faculty, University of Defence, Trebesska 1575, Hradec Kralove 500 01, Czech Republic. Electronic address: roman.chlibek@unob.cz.
Jan Smetana: Military Medical Faculty, University of Defence, Trebesska 1575, Hradec Kralove 500 01, Czech Republic. Electronic address: jan.smetana@unob.cz.
Kate��ina Kybicov��: National Reference Laboratory for Lyme Borreliosis, National Health Institute, ��rob��rova 49/48, Prague 10, 100 00, Czech Republic. Electronic address: katerina.kybicova@szu.cz.
Martina Malikova: Military Medical Faculty, University of Defence, Trebesska 1575, Hradec Kralove 500 01, Czech Republic. Electronic address: martina.malikova@unob.cz.
Frederick J Angulo: Global Vaccines and Anti-infectives Medical Affairs, Pfizer Inc., Collegeville, 500 Arcola Road, PA 19426, USA. Electronic address: frederick.angulo@pfizer.com.
Alexandra Loew-Baselli: Global Vaccines and Anti-infectives Medical Affairs, Pfizer Corporation Austria, Floridsdorfer Hauptstra��e 1, Vienna 1210, Austria. Electronic address: alexandra.loew-baselli@pfizer.com.
Ye Tan: Evidence Generation Statistics, Pfizer Inc., 1 Portland Street, Cambridge, MA 02139, USA. Electronic address: ye.tan@pfizer.com.
Ale�� Ond��ej����ek: Pfizer spol. s r.o., Stroupe��nick��ho 3191/17, Praha 5, 150 00, Czech Republic. Electronic address: ales.ondrejicek@pfizer.com.
Gordon Brestrich: Global Vaccines and Anti-infectives Medical Affairs, Pfizer Pharma GmbH, Friedrichstra��e, Berlin 110-10117, Germany. Electronic address: gordon.brestrich@pfizer.com.
Andreas Pilz: Global Vaccines and Anti-infectives Medical Affairs, Pfizer Corporation Austria, Floridsdorfer Hauptstra��e 1, Vienna 1210, Austria. Electronic address: andreas.pilz@pfizer.com.
Jennifer C Mo��si: Global Vaccines and Anti-infectives Medical Affairs, 23 Avenue du Docteur Lannelongue, Paris 75014, France. Electronic address: jennifer.moisi@pfizer.com.
James H Stark: Global Vaccines, and Anti-infectives Medical Affairs, Pfizer Inc., 1 Portland Street, Cambridge, MA 02139, USA. Electronic address: james.h.stark@pfizer.com.
INTRODUCTION: Lyme borreliosis (LB), an infection caused by Borrelia burgdorferi sensu lato (Bbsl), is the most common tick-borne disease in Europe. To further characterize the LB burden in the Czech Republic, we conducted a seroprevalence study and estimated the incidence of symptomatic Bbsl infections. METHODS: Anti-Bbsl IgM and IgG antibodies were detected in sera collected from the adult population in 2011���-2012 by enzyme-linked immunosorbent assay and immunoblot tests at the National Reference Laboratory. The incidence of symptomatic Bbsl infections was estimated from the seroprevalence results and the symptomatic proportion and duration of persistence of anti-Bbsl IgG antibodies in Bbsl-infected individuals. Surveillance under-detection of symptomatic Bbsl infections was estimated by comparing surveillance-reported and seroprevalence-based incidence. RESULTS: Samples from 1996 adults were tested; the median age (range) was 45 (18���-87) years; 1037 (52.0���%) were female. The prevalence (with 95���% confidence interval) of anti-Bbsl IgG, and IgM and/or IgG (IgM/IgG) antibodies was 6.3���% (5.3���-7.5���%), and 9.5���% (8.3���-10.9���%), respectively. The IgM/IgG prevalence was 7.8���% (6.5���-9.2���%) in Bohemia and 15.3���% (12.2���-19.0���%) in Moravia. There were an estimated 30,563 (26,550���-34,962) symptomatic incident Bbsl infections in adults in the Czech Republic in 2012, for an incidence of 352.2 (306.0���-402.9) symptomatic Bbsl infections per 100,000 adults per year. There were an estimated 11 (10���-13) symptomatic Bbsl infections for each surveillance-reported LB case in the Czech Republic in 2012. CONCLUSIONS: There is high incidence of symptomatic Bbsl infections in the Czech Republic, particularly in Moravia. Interventions are needed to address the substantial burden of LB in the Czech Republic.
